EDEN PRAIRIE, Minnesota, 20 December 2021 / PRNewswire / – NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) (“NeuroOne” or the “Company”), a medical technology company focused on improving surgical care options and outcomes for patients with neurological disorders , was featured on The medical aisle podcast, in an episode entitled “A conversation with Dave rosa, President and CEO, NeuroOne. “
Summary of the episode:
“Join us for a conversation with Frank Jaskluke and Dave rosa, President and CEO of NeuroOne Medical Technologies Corporation. Dave shares more information about the innovation underway at NeuroOne, which is developing high-definition thin-film electrodes that can be used for a variety of neurological conditions, including epilepsy. “
The episode is also available on podcast platforms including Medical Alley, Apple, and Spotify:
Medical aisle: https://medicalalleypodcast.org/episodes/a-conversation-with-dave-rosa-president-and-ceo-neuroone
NeuroOne Medical Technologies Corporation is a developmental company committed to providing minimally invasive and high definition solutions for EEG recording, brain stimulation and ablation solutions to patients with epilepsy, Parkinson’s disease, dystonia, essential tremors, chronic pain from failed back surgery, and other related neurological conditions that can improve patient outcomes and reduce procedural costs. For more information visit https://www.n1mtc.com .
The podcast may include forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Except for statements of historical fact, any information contained in this presentation may be a forward-looking statement that reflects the Company’s current views on future events and is subject to known and unknown risks, uncertainties and other factors. that may cause our actual results, levels of activity, performance or achievements to be materially different from information expressed or implied by such forward-looking statements. In certain cases, you can identify forward-looking statements by the words or expressions “could”, “could”, “will”, “could”, “should”, “should”, “expect”, “the intention”. “,” Plan, “” objective “,” anticipate “,” believe “,” estimate “,” predict “,” project “,” potential “,” target “,” seek “,” contemplate “,” continue “, “focused on,” “committed to” and “ongoing”, or the negative of those terms, or other comparable terminology intended to identify statements regarding the future. Although the Company believes that we have a reasonable basis for each forward-looking statement, we caution you that such statements are based on a combination of facts and factors known to us now and our expectations for the future, of which we cannot be certain. Our actual future results may differ materially from what we would expect due to factors largely beyond our control, including risks and uncertainties relating to the market and other conditions, the impact of economic, industrial or general political conditions in the United States or internationally and those described under the heading “Risk Factors” in our documents filed with the Securities and Exchange Commission. These forward-looking statements speak only as of the date of the podcast, and the Company assumes no obligation to revise or update any forward-looking statements for any reason, even if new information becomes available in the future.
View original content to download multimedia: https://www.prnewswire.com/news-releases/neuroone-featured-on-the-medical-alley-podcast-a-conversation-with-dave-rosa-president-and -ceo -neurone-301448190.html
SOURCE NeuroOne Medical Technologies Corporation